For several weeks PerkinElmer, Inc. has been collecting nominations for a variety of Global Innovation Awards across all companies of the Group. EUROIMMUN has also suggested five colleagues from its different development departments for the awards.
On Wednesday, 15 December 2021, the award winners were finally announced and received their awards in a digital ceremony.
Among the roughly 100 winners are three young scientists from EUROIMMUN who each received an Early Innovator Award for their excellent work for the development of innovative products and solutions over the past two years.
The first was Christodoulos Filippis, project manager in the department for real-time PCR tests, who received the award for the rapid development of the EURORealTime-SARS-CoV-2 and the EURORealTime-SARS-CoV-2/Influenza A/B, which has created significant revenue for EUROIMMUN over the past 18 months.
Fabian Lindhorst, team leader in the area of infection serology, also received an Early Innovator Award for his leading role in the development of the first CE-marked Anti-SARS-CoV-2 ELISA based on the S1 protein of the coronavirus, which could already be placed on the market in February 2020.
The third colleague to receive an award was Lisa Honold, head of department of Immunoblots/Food Sensitivity Diagnostics, for her valuable contributions in connection with the cooperation between PerkinElmer/EUROIMMUN and EverlyWell, an US supplier of at-home lab tests, as well as for her work on dried blood spot applications in allergy and food sensitivity diagnostics.
In addition, EUROIMMUN received the Patent Award as the most innovative company in the PerkinElmer Group because of its high number of filed and granted patents. Lars Komorowski and Christian Probst accepted the award on behalf of all development teams involved.
Our congratulations to the award winners! We thank them and their whole teams for their great efforts and outstanding achievements.
